CRISPR cell therapy trial for tough lupus cases withdrawn before starting
Disease control
Terminated
This early-stage study aimed to test the safety and initial effects of a single infusion of CB-010, a new type of cell therapy modified with CRISPR gene-editing, in adults with severe lupus that hasn't responded to standard treatments. The trial was designed to last about two yea…
Phase: PHASE1 • Sponsor: Caribou Biosciences, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC